Pfizer IncChange company Symbol lookupSelect an option...PFE Pfizer IncVIVHY Vivendi SEEBET Ebet IncPDI PIMCO Dynamic Income FundBXRX Baudax Bio IncBAC Bank of America CorpSPRU Spruce Power Holding CorpSRNEQ Sorrento Therapeutics IncSPI SPI Energy Co LtdAMC AMC Entertainment Holdings IncGo
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
VIVHY Vivendi SE
EBET Ebet Inc
PDI PIMCO Dynamic Income Fund
BXRX Baudax Bio Inc
BAC Bank of America Corp
SPRU Spruce Power Holding Corp
SRNEQ Sorrento Therapeutics Inc
SPI SPI Energy Co Ltd
AMC AMC Entertainment Holdings Inc
Health Care : Pharmaceuticals | Large Cap Value
Company profilePfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q2 ending 06/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced August 1, 2023 | $0.67 | Q2 Consensus of 17 analysts | $0.57 | Difference from consensus | 17.96% | Q3 Earnings will announce | (Unconfirmed) October 31, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
PFE's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.